Is Tarlatamab currently available to domestic patients?

Up to now, Tarlatamab (Tarlatamab, trade name Imdelltra) has not been officially launched in China, and patients cannot purchase it directly through local hospitals or pharmacies. The drug has received accelerated approval from the FDA in the United States in May 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after receiving more than two lines of platinum-based chemotherapy. Although there are phase II clinical studies (DeLLphi‑307 trial) for the Chinese population that are recruiting patients, these clinical trials are only for specific patient groups, and the drug use must be completed within the scope of the trial institution and protocol, and cannot be equivalent to market use.

International data show that talatumumab has demonstrated significant efficacy in platinum-resistant small cell lung cancer due to its bispecific T cell engagement mechanism (DLL3 and CD3): DeLLp The hi‑301 study showed an objective response rate (ORR) of approximately 40% and a median response duration of 9.7 months. Such strong efficacy indicators support its rapid advancement in the European and American markets, but in China it still needs to go through a series of registered clinical studies and approval procedures to achieve market launch and medical insurance coverage.

If Chinese patients want to use talatumumab, they usually can only do so in two ways: one is to participate in ongoing clinical trials, such as the clinical validation phaseDeLLphi‑307; The second is to apply for emergency use through "single subject IND" or "overseas drug purchase". However, these routes are complex, time-consuming, and involve multiple issues such as law, ethics, and cost, and are not suitable for large-scale promotion. Currently, there are no approved talatumumab products circulating in China, and there is no medical insurance or commercial insurance support. Patients need to carefully evaluate the related risks and feasibility.

To sum up, talatumumab is still in the clinical trial stage in China and has not yet been included in medical insurance and has not been put into circulation. If patients consider using this drug, they should pay attention to the recruitment information of relevant domestic clinical trial centers. If they meet the conditions, they can participate; if the conditions are not met, they can communicate with the attending doctor and inquire whether there are feasible options such as single-subject use or cross-border drug purchase. At the same time, you must also understand the cytokine release syndrome (CRS) that this drug may cause.), neurotoxicity (ICANS) and other potential risks, and the medication must be used safely under professional monitoring.

Reference materials:https://www.drugs.com/seladelpar.html